7.31
-0.29(-3.82%)
Currency In USD
| Previous Close | 7.6 |
| Open | 7.41 |
| Day High | 7.5 |
| Day Low | 7.15 |
| 52-Week High | 18.8 |
| 52-Week Low | 5.98 |
| Volume | 6,603.76 |
| Average Volume | 167,188 |
| Market Cap | 190.09M |
| PE | -5.5 |
| EPS | -1.33 |
| Moving Average 50 Days | 7.12 |
| Moving Average 200 Days | 9.23 |
| Change | -0.29 |
If you invested $1000 in Cartesian Therapeutics, Inc. (RNAC) since IPO date, it would be worth $17.4 as of March 03, 2026 at a share price of $7.31. Whereas If you bought $1000 worth of Cartesian Therapeutics, Inc. (RNAC) shares 5 years ago, it would be worth $60.31 as of March 03, 2026 at a share price of $7.31.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
GlobeNewswire Inc.
Jan 09, 2026 1:04 PM GMT
Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to com
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
GlobeNewswire Inc.
Dec 18, 2025 9:05 PM GMT
FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
GlobeNewswire Inc.
Nov 13, 2025 9:05 PM GMT
100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3) D